Society should seriously consider the benefits of a formal transfer of liability from drugmakers to the state for new drug approvals, subject to requirements for the full transparency of clinical data, writes biopharma consultant David Grainger. Drugmakers would no longer be held responsible for events they could not foresee but could still be liable for any manufacturing defects, he writes.

Full Story:

Related Summaries